23rd IFPMA Assembly

11 - 12 October 2006 Hotel President Wilson, Geneva, Switzerland

11 - 12 October 2006


12:15 to 22:00


Hotel President Wilson, Geneva, Switzerland


This event has now passed. To browse our upcoming events click here.

The IFPMA is developing a stimulating Assembly
program that reflects the unique dynamics of our
home city, which plays host to a range of such
key global organizations as the World Health
Organization, the World Trade Organization and
the World Intellectual Property Organization.
Interactive panel sessions will bring together high
profile guest speakers with top pharmaceutical
leaders and researchers to address major
questions affecting healthcare worldwide:
• How can we in industry best manage the major
issue of the Health Challenges in the UN’s
Millennium Development Goals?
• How do we respond to pressures to provide
access to new medicines for diseases of both
the developed and developing world?
• How do today’s national healthcare systems
help or hinder quality of care?
• What are the pharmaceutical sector and
other players doing to combat the threat of
pandemic influenza?
You will receive more information shortly, but make
sure you are free to attend this exciting event!


Wednesday, 11 October 2006

(All events are in “WI” Conference Room, Hotel President Wilson, unless specified elsewhere)


Registration Desk Opens (“Wilson Foyer”, downstairs from “Lobby Lounge”)

12h15 – 13h30

Opening Luncheon (“Lobby Lounge”, Hotel President Wilson)
Speakers introduced by Dr. Daniel Vasella, President, IFPMA, Chairman & CEO, Novartis
Mr. André Hédiger, Mayor of Geneva
Ms. Christine Beerli, Chairwoman of the Board, Swissmedic
Mr. Thomas Zeller, Deputy Director, Thematic & Technical Resources Department,
Swiss Agency for Development & Cooperation

14h00 – 14h15

Outgoing President’s Remarks
Dr. Daniel Vasella, President, IFPMA, Chairman & CEO, Novartis

14h15 – 15h45

Meeting the Millennium Development Goal Health Challenges
What are the challenges to achieving the Millennium Development Goals in health and
what are the solutions?
Mr. Andrew Jack, Financial Times (Moderator)
Mr. Haruo Naito, President & CEO, Eisai Co. Ltd.
Ms. Joy Phumaphi, Assistant Director-General, Family & Community Health, WHO
Dr. Michel Zaffran, Deputy Executive Secretary, GAVI Alliance
Ms. Regina Kamoga, Country Manager, CHAIN, Uganda & Board Member, IAPO
(Followed by audience participation)

16h15 – 17h45

Health Care System Choices in Emerging Countries
How are leaders of rapidly developing countries adapting their healthcare systems to
meet changing patient needs?
Mr. Michael Waldholz, Bloomberg (Moderator)
Dr. Howard Zucker, Assistant Director-General, Health Technology &
Pharmaceuticals, WHO
Dr. Jacques Baudouy, Director of Health, Nutrition & Population, World Bank
Dr. Pavel Hrobon, Chairman, Health Reform CZ, Czech Republic
Dr. Anil Patel, Action Research in Community Health & Development, India
Prof. Manuel Ruiz De Chávez, Executive President, FUNSALUD, Mexico
(Followed by audience participation)

19h30 – 22h00

Reception & Dinner (Grand Théâtre, Place Neuve, Geneva)
The pre-dinner speaker is Mr. Pascal Lamy, Director-General, WTO

Thursday, 12 October 2006

(All events are in “WI” Conference Room, Hotel President Wilson, unless specified elsewhere)

08h00 – 08h45

Press Briefing — for Invited Media Only
Outgoing IFPMA President, Dr. Daniel Vasella
Incoming IFPMA President, Mr. Fred Hassan
IFPMA Director General, Dr. Harvey Bale

09h00 – 10h30

The Future of Pharmaceutical Innovation?
Where is pharmaceutical research going and what do we need to meet future public
health needs?
Mr. Michael Waldholz, Bloomberg (Moderator)
Dr. Hatsuo Aoki, President of JPMA, Co-Chairman of Astellas Pharma Inc.
Prof. Trevor Jones, Chairman of ReNeu, BAC & People in Health
Dr. Swati Piramal, Director, Nicholas Piramal India, Ltd.
Prof. Desmond Sheridan, Academic Cardiology Unit, Imperial College, UK
Dr. Donald Francis, Executive Director, Global Solutions for Infectious Diseases
(Followed by audience participation)

11h00 – 12h30

R&D for Neglected Diseases
What are the appropriate roles of OECD governments, developing country governments,
NGOs and pharmaceutical companies in R&D for the diseases that specifically
impact LDCs?
Mr. Michael Waldholz, Bloomberg (Moderator)
Prof. Paul Herrling, Head of Corporate Research, Novartis
Dr. Robert Ridley, Director, Research and Training in Tropical Diseases
Dr. Chris Hentschel, CEO, Medicines for Malaria Venture
Dr. Bernard Pécoul, Executive Director, Drugs for Neglected Diseases initiative
Ms. Anne-Laure Ropars, Pharmaceutical R&D Policy Project
(Followed by audience participation)

12h30 – 13h45

Luncheon (“Lobby Lounge”, Hotel President Wilson)
The lunch speaker is the Incoming President of the IFPMA, Mr. Fred Hassan,
Chairman & CEO, Schering-Plough

14h00 – 14h30

Keynote speaker
Dr. Anders Nordström, Acting Director-General, WHO

14h30 – 16h00

Healthcare Systems in Transition: the impact on quality of healthcare?
How are factors such as price controls and reference pricing, reimbursement and
insurance systems, ageing populations and the development of health tourism
impacting health care in the US, EU and Japan?
Mr. Andrew Jack, Financial Times (Moderator)
Mr. Christopher Singer, Executive Vice President and COO, PhRMA
Prof. Koichi Kawabuchi, Tokyo Medical & Dental University
Prof. Panos Kanavos, International Health Policy, London School of Economics
Prof. Hans Rosling, International Health, Karolinska Institute, Sweden
(Followed by audience participation)

16h00 – 17h00

Challenges in Fighting Avian & Pandemic Influenza
What are the appropriate roles for the public and private sectors in innovation,
preparedness, supply, safety and liability issues, with regard to the avian and
pandemic influenza threats?
Mr. Andrew Jack, Financial Times (Moderator)
Dr. Jörg Reinhardt, CEO, Novartis Vaccines & Diagnostics
Prof. John Oxford, Queen Mary’s School of Medicine and Dentistry, UK
Prof. Antoine Flahault, Avian Influenza Task Force Leader, France
Dr. Bruce Gellin, Director, National Vaccine Program Office, USA
(Followed by audience participation)

17h00 – 17h45

Advancing the fight against counterfeit medicines
How can we strengthen the partnership between public and private sectors to raise
awareness and increase effectiveness of anti-counterfeiting measures?
Dr. Harvey Bale, Director General, IFPMA (Moderator)
Ms. Judith Oulton, CEO, International Council of Nurses
Ms. Regina Kamoga, Country Manager, CHAIN, Uganda & Board Member, IAPO
Mr. Thomas Kubic, Executive Director, Pharmaceutical Security Institute

19h30 – 22h00

Reception & Dinner (Musée Ariana, Avenue de la Paix, Geneva)
The pre-dinner speaker is Mr. Gilles Pajot, President, Global Business Management,
IMS Health


Dr. Hatsuo Aoki President of JPMA, Co-Chairman of Astellas Pharma Inc.

Dr. Hatsuo Aoki has been Co-Chairman of Astellas Pharma Inc. since 27 June 2006 and
President of the Japan Pharmaceutical Manufacturers Association since 19 May 2004.
Previously, he was President and Chief Executive Officer of Fujisawa Pharmaceutical
Co., Ltd. until the merger between Yamanouchi and Fujisawa on 1 April 2005. While
at Fujisawa, he worked in the Research and Development Division and the Ethical
Pharmaceuticals Division. He was also Chairman and Chief Executive Officer of
Fujisawa USA, Inc, from 1993 to 1995. Dr. Aoki received The Technology Award
from the Agricultural and Biological Society of Japan in 1988, the Appreciation Award
for Long Term Contribution to the Development of the Pharmaceutical Industries from
the Osaka Prefectural Governor in 1996 and the National Commendation for Invention:
Invention Practice Service Prize from the Japan Institute of Invention and Innovation
in 2004.

Dr. Harvey Bale Director General, IFPMA

Dr. Harvey E. Bale, Jr. is the Director-General of the International Federation of
Pharmaceutical Manufacturers & Associations, IFPMA. Previously he was Senior
Vice President for International Affairs with the Pharmaceutical Research and
Manufacturers of America. Prior to that he was International Manager at Hewlett-
Packard. He also served 12 years in the Office of the U.S. Trade Representative. In
1980 he was on special White House assignment to the Middle East Camp David
negotiations. In 1986 he received the Distinguished Service Award from President of
the United States Ronald Reagan. In 1996-1997, he taught a post-graduate course
on intellectual property and technology strategy at Georgetown University. Dr. Bale
received a Ph.D. in Economics from the University of Maryland and a B.A. from
Temple University.

Dr. Jacques Baudouy Director of Health, Nutrition & Population, World Bank

Dr. Jacques Baudouy has been Director for Health, Nutrition and Population, Human
Development Network since 1 July 2003. In his previous assignment at the World
Bank, Dr. Baudouy was Director of the Human Development Sector in the Middle East
and North Africa Region from 1996 until June 2003. Dr. Baudouy joined the World
Bank in 1984, in the Africa Region, as Principal Public Health Specialist, responsible
for several health, population and social programs in various countries. Prior to joining
the World Bank, Dr. Baudouy acquired extensive experience in health sector policy
and management (consultancies for USAID and EC), community-based development
(operational research with the Harvard Institute for International Development) and
relief operations (with the French NGO Doctors without Borders).

Ms. Christine Beerli Chairwoman of the Board, Swissmedic

Ms. Christine Beerli has been serving as Chairwoman of the Board of Swissmedic,
the Swiss Regulator for Medicines and Healthcare Products, since 1 January 2006.
Qualified as an attorney-at-law, Ms. Beerli worked as a self-employed lawyer in
Biel-Bienne from 1979 to 1997. Since 1998, she has been Dean of the Department
of Engineering and Information Technology at the University of Applied Sciences in
Berne. She has been a Member of the Swiss Parliament for 12 years in the Council
of States (upper house) and leader of the parliamentary group of the Liberal Party
for 6 years.

Prof. Antoine Flahault Avian Influenza Task Force Leader, France

Prof. Antoine Flahault, MD, PhD, is Professor of Public Health at the Pierre & Marie
Curie University, France. He also heads the Public Health Department at the University
Hospital Tenon in Paris and leads a research team at the Institut National de la Santé
et de la Recherche Médicale (UMR-S 707). Director of the WHO Collaborating Centre
for Electronic Disease Surveillance, he is coordinating a program which combines
disease surveillance, mathematical modelling and epidemiology. He is also responsible
for the National System of Communicable Disease Surveillance in General Practice
in France (called Réseau Sentinelles http://www.sentiweb.fr), and has developed
with the WHO the FluNet system for global monitoring of influenza. He has been
recently designated by the French Prime Minister to set up a panel to coordinate
research on Chikungunya. By 1 September 2006, he had 158 published references
quoted in PubMed.

Dr. Donald Francis Executive Director, Global Solutions for Infectious Diseases

Donald P. Francis, M.D., D.Sc., co-founded Global Solutions for Infectious Diseases
in 2004 and has served since then as its Chairman, Executive Director and Chief
Medical Officer. Dr. Francis has over 30 years experience in epidemic control and
vaccines. He spent 21 years working for the U.S. Centers for Disease Control (CDC),
focusing on vaccine-preventable diseases such as measles, cholera, smallpox, and
hepatitis B and has worked on HIV/AIDS since its emergence in 1981. He initially
directed the AIDS laboratory at the CDC and worked closely with the Institut Pasteur
to identify the causative virus. After his retirement from the CDC in 1992, he joined
Genentech to help develop vaccines. He also helped found what became the
International AIDS Vaccine Initiative (IAVI) and started a new company, VaxGen, to
work on an HIV vaccine.

Dr. Bruce Gellin Director, National Vaccine Program Office, USA

As Director of the National Vaccine Program Office (NVPO) and the Chair of the
Secretary’s Task Force on Influenza Preparedness at HHS, Dr. Bruce Gellin is a top
US expert on vaccines and infectious diseases. He was previously Director of the
National Network for Immunization Information and has held positions at the National
Institute of Allergy and Infectious Diseases (NIH), the Centers for Disease Control and
Prevention (CDC), the Rockefeller Foundation, and Johns Hopkins University School
of Public Health. In addition, he has been a regular consultant to the World Health
Organization. He teaches at Columbia University School of Public Health, George
Washington University School of Medicine, and Vanderbilt University Schools of
Medicine and Nursing. Dr. Gellin is a graduate of the University of North Carolina
(Morehead Scholar), Cornell University Medical College, and the Columbia University
School of Public Health.

Mr. Fred Hassan Incoming President of the IFPMA and Chairman & CEO, Schering-Plough

Fred Hassan is chairman of the board and chief executive officer of Schering-Plough
Corporation. Prior to joining Schering-Plough in April 2003 and assuming his current
position, Mr. Hassan was chairman and chief executive officer of Pharmacia Corporation.
He joined the former Pharmacia & Upjohn in May 1997 as chief executive officer and
was elected to the Board of Directors. In February 2001, Mr. Hassan was named
chairman of the Board of Pharmacia. Previously, Mr. Hassan was executive vice president
of Wyeth, formerly known as American Home Products, with responsibility for its
pharmaceutical and medical products business. He was elected to Wyeth’s Board
of Directors in 1995. Mr. Hassan also spent 17 years with Sandoz Pharmaceuticals
(now Novartis) and headed its U.S. pharmaceuticals business. He is the past chairman
of the Board of Directors of the Pharmaceutical Research and Manufacturers
of America (PhRMA) and is the immediate past chairman of the HealthCare Institute
of New Jersey.

Mr. André Hédiger Mayor of Geneva

Mr. André Hédiger is Mayor of Geneva for 2006-07 and has held this office four times
before. He has also headed the city’s Sports and Security Department continuously since
1987, when he was first elected to the city’s Executive Council (Conseil administrative). A
trade unionist since 1960, he then joined the Swiss Labour Party (Parti Suisse du Travail),
becoming a Central Committee member in 1975. He was first elected to the City Council
(Conseil municipal) in 1967. He was a principal advocate of Geneva’s new sports
stadium, the Stade de Genève and has sought to make Geneva more multicultural.

Dr. Chris Hentschel CEO, Medicines for Malaria Venture

Dr. Chris Hentschel is President and Chief Executive Officer, Medicines for Malaria
Venture (MMV) in Geneva, Switzerland. MMV is a nonprofit organization created to
discover, develop and deliver affordable new antimalarials. His early career focused
on basic biomedical research at Imperial Cancer Research Fund, London, as
lecturer at the Swiss Federal Institute of Technology (ETH) in Zurich and as a Fogarty
Fellow, National Institutes of Health, USA. From 1978–1997, he was Chief Executive
Officer/Scientific Director, UK Medical Research Council’s Collaborative Centre.
In 1999, he became a senior research fellow at the Emerging Technology Program,
Wharton Business School. He is also a non-executive Director to two biotechnology
companies, advisor to a European venture capital fund and Member of the
Supervisory Board of the Global Medical Forum in Zurich.

Prof. Paul Herrling Head of Corporate Research, Novartis

Professor Paul Herrling has been Head of Corporate Research at Novartis since 2002.
He is Chairman of the Board of the Novartis Institute for Tropical Diseases in Singapore,
oversees the Friedrich Miescher Institute in Basel, Switzerland and is on the boards
of the Genomics Institute of the Novartis Research Foundation in La Jolla California
and several other research institutes. Previously Head of Global Research at Novartis
Pharma, he joined Sandoz Pharma in 1975 and held various research positions in
both Sandoz and Wander. He is Professor of Drug Discovery Science at the University
of Basel, Switzerland and serves on the Board of Trustees of The Scripps Research
Institute, the Board of the ETH (Swiss Federal Institutes of Technology) and the
Scientific Advisory Committee of the Drugs for Neglected Diseases Initiative (DNDi).

Dr. Pavel Hrobon Chairman, Health Reform CZ, Czech Republic

Pavel Hrobon is a co-founder and chairman of the think-tank Health Reform, Czech
Republic, whose aim is to prepare and support implementation of a substantial overhaul
of the Czech health care system. From 2002-2004, he advised the CEO of the General
Health Insurance Fund (VZP) of the Czech Republic and in 2005 worked for VZP as
a director of strategy. From 1998-2002, Pavel Hrobon worked as a consultant for the
Prague office of McKinsey & Company. At McKinsey, he advised clients on health care,
insurance and banking issues in several European countries. Pavel Hrobon has an M.D.
from the Charles University in Prague and a Master of Science degree in Health Policy
and Management from the Harvard School of Public Health. He also has experience
practicing medicine and teaching public health at the Charles University in Prague.

Mr. Andrew Jack Pharmaceuticals Correspondent, Financial Times

Andrew Jack is the pharmaceuticals correspondent at the Financial Times. Since
joining the FT in 1990, he has held a series of posts, including accounting and tax
correspondent, Paris correspondent, and Moscow bureau chief. He was one of a
group of journalists to be awarded the 1993 British Press Awards Reporting Team
of the Year accolade for coverage of the Robert Maxwell affair. He was twice named
the Association of Chartered Certified Accountants’ accountancy journalist of the year,
and won the French Insurers’ Association annual journalist’s award. The most recent
edition of his latest book, ‘Inside Putin’s Russia’, was published in paperback in the
US by Oxford University Press at the end of 2005 and in the UK by Granta. He is
also the author of ‘The French Exception’ (Profile Books/Editions Odile Jacob), and
previously wrote the specialist reports ‘Insurance in France’ (Pearson), ‘Networking’
and ‘Life at the top’ (Industrial Society).

Prof. Trevor Jones Chairman of ReNeu, BAC & People in Health

Prof. Trevor M. Jones CBE is a Director of Allergan Inc (USA) and Senior R&D Advisor
to Esteve SA (Spain) and Servier (France). He is also Deputy Chairman of Council,
visiting professor at King’s College, London, Chairman of the UK stem cell biotech
company ReNeuron Ltd, the Dutch Biotech ligand company BAC BV and the
European company People in Health, as well as being a member of the Board
of NextPharma Technologies Ltd. He is a founder member of the Geneva-based
Medicines for Malaria Venture (MMV) and in 2004 was appointed to the World Health
Organisation (WHO) Commission on Intellectual Property Rights, Innovation and
Public Health (CIPIH). For 10 years until September 2004, he was Director General
of the Association of the British Pharmaceutical Industry (ABPI), a member of Council
of IFPMA and a member of the Board of EFPIA. In 2005, he was the winner of the
SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences
and industry. He was honoured by Her Majesty Queen Elizabeth II with the award of
a CBE in 2003.

Ms. Regina Kamoga Country Manager, CHAIN, Uganda & Board Member, IAPO

Ms. Regina M. Namata Kamoga is the Uganda Country Manager and IAPO representative
for the Community Health And Information Network (CHAIN), an organization
founded in 1998 by a group of African professionals resident in the United Kingdom.
Since setting up CHAIN Uganda, Ms. Kamoga has been actively addressing the plight
of patients and particularly HIV/AIDS patients, helping capacity building in NGOs and
CBOs in governance and policy issues, treatment literacy and access, building and
strengthening networks. She has worked with other patients organizations in Uganda
to address issues of patient-centered health care. She is also vice chairperson of the
Uganda Indigenous Knowledge Society (UGKIS), an association that promotes the
use of indigenous knowledge practices that can be integrated into the development
process. She is also a part-time lecturer at Makerere University, Faculty of Forestry
and Nature Conservation.

Prof. Panos Kanavos International Health Policy, London School of Economics

Prof. Panos Kanavos is lecturer in International Health Policy in the Department of Social
Policy and Merck Fellow in Pharmaceutical Economics at LSE Health and Social Care.
He has acted as advisor to a number of intergovernmental and non-governmental organizations,
including the World Bank, the World Health Organization and the Organization
for Economic Co-operation and Development, the American Association for Retired
Persons and the Ministries of Health in more than 14 transition and developing countries.
His research interests include comparative health policy and health care reform; pharmaceutical
policy; and the socio-economic determinants of health.

Prof. Koichi Kawabuchi Tokyo Medical & Dental University

Koichi Kawabuchi was accepted as Professor of the Center for Health Care Economics
at the Tokyo Medical and Dental University in 2000. He is currently exploring the applicability
of Diagnosis Related Groups (DRGs) to Japan and doing a comparative study
of health care systems in other countries. His most recent paper, published in 2005,
is titled “Is Koizumi’s Health Care ‘Reform’ Going Well?” Since 1998, Prof. Kawabuchi
has also been involved in a field study as Chief Senior Researcher of the Japan Medical
Association Research Institute. From 1998 to 1999, Mr. Kawabuchi was a professor
of Health Care Economics at the Nihon Fukushi University, Aichi-Ken, Japan. His main
field of research was Health Economics and Health Policy in Japan. In 1998, he wrote
an “Introduction to Health Care Economics in Japan – Understanding Japanese Health
Care Reform”. He received his MBA in Health Administration from the University of
Chicago’s Graduate School of Business in 1987.

Mr. Thomas Kubic Executive Director, Pharmaceutical Security Institute

Mr. Thomas T. Kubic is a former US Federal Law Enforcement Executive with
national and international investigative experience. Since 2002, he has headed the
Pharmaceutical Security Institute (PSI), which works to protect public health by ensuring
the integrity of pharmaceuticals. Under his leadership, PSI has been reorganized to
emphasize information sharing and private-public sector cooperation. Major advances
have included the development of the PSI Anti-counterfeiting Strategy with five supporting
programs and the Counterfeit Incident Reporting System. Mr. Kubic has provided
testimony to senior government officials around the world about the international
nature of counterfeiting and its devastating impact. He currently serves on the Interpol
Intellectual Property Crime Action Group, advises the Permanent Forum against
International Pharmaceutical Counterfeiting and is an officer of the Partnership for
Safe Medicines.

Mr. Pascal Lamy Director-General, WTO

Mr. Pascal Lamy has been Director-General of the World Trade Organization (WTO)
since September 2005. Between 1999 and 2004, Mr. Lamy was Commissioner for
Trade at the European Commission under Romano Prodi. In November 1994, he
joined the team in charge of rescuing the French bank Credit Lyonnais and later
became CEO of the bank until its privatisation in 1999. In Brussels from 1985 to
1994, he was Chief of staff for the President of the European Commission, Jacques
Delors, and his Sherpa representative at the G7. After his tenure in Brussels, Mr. Lamy
spent a short sabbatical period as President of “Notre Europe”, a think tank working
on European integration, as associate Professor at the l’Institut d’Études Politiques in
Paris and as advisor to Poul Nyrup Rasmussen (President of the European Socialist
Party). Mr. Lamy holds degrees from the Paris-based Ecole des Hautes Etudes
Commerciales (HEC), from the Institut d’Etudes Politiques (IEP) and from the Ecole
Nationale d’Administration (ENA).

Mr. Haruo Naito President & CEO, Eisai Co. Ltd.

Mr. Haruo Naito has been President and CEO of Eisai Co., Ltd. of Japan since 1988
and instituted the company’s new strategic orientation focusing on active participation
in numerous facets of human health care delivery systems. Under his leadership, Eisai
has established a global strategic research network, consisting of research centers in
the USA, Europe and Asia. In addition, Eisai now has business activities in some forty
countries throughout the world. Mr. Naito currently serves on Northwestern University’s
Kellogg Advisory Board and Duke University’s Fuqua Board of Visitors. He also serves
as Vice President of the International Pharmaceutical Manufacturers & Associations
(IFPMA). In April 1999, he was awarded an honorary CBE by the United Kingdom in
recognition of his long-standing efforts in strengthening UK – Japan relations.

Dr. Anders Nordström Acting Director-General, WHO

Dr. Anders Nordström, who comes from Sweden, is Acting Director-General of the
World Health Organization until the election of a new Director-General in November
2006. His three priorities for this interim period are: to maintain momentum and direction
in WHO’s technical work; to manage the election process efficiently and transparently;
and to continue work on management reforms. Dr. Nordström took office as Assistant
Director-General for General Management in July 2003 with a mandate to support the
implementation of Dr Lee Jong-Wook’s vision of a more effective and efficient WHO
that is equipped to “do the right things, in the right place”. In 2002, he was the Interim
Executive Director for the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior
to joining WHO, he was strongly engaged in global health policy dialogue, with a
special focus on issues relating to health systems and human resources.

Ms. Judith Oulton CEO, International Council of Nurses

Ms. Judith A. Oulton was appointed Chief Executive Officer of the Geneva-based
International Council of Nurses (ICN) in March 1996 and is also CEO of the Florence
Nightingale International Foundation. Prior to joining ICN, Ms. Oulton served as
Executive Director of the Canadian Nurses Association (CNA) and the Canadian
Nurses Protective Society. Her career has included experience: in government
as Senior Nursing Consultant with major responsibility in hospital organization and
budgetary audits; in education as a professor in the Nursing Faculty, University
of New Brunswick; and in nursing administration and service in a variety of clinical
areas. She has presented in many countries around the world and has published
many articles in professional reviews.

Prof. John Oxford Queen Mary’s School of Medicine and Dentistry, UK

John Oxford is Professor of Virology at St Bartholomew’s and the Royal London
Hospital, Queen Mary’s School of Medicine and Dentistry. He has co-authored two
standard texts: ‘Influenza, the Viruses and the Disease’ with Sir Charles Stuart-Harris
and G.C. Schild and, most recently, ‘Human Virology, a Text for Students of Medicine,
Dentistry and Microbiology’. Prof. Oxford has also published some 250 scientific
papers. His research interest is the pathogenicity of influenza, in particular the 1918
Spanish Influenza strain, which he combines with conducting clinical trials using new
influenza vaccines and antiviral drugs. This research has featured in TV programs
shown in the UK, USA, Germany and Holland. He is Scientific Director of the college
research virology company Retroscreen Virology (www.retroscreen.com).

Mr. Gilles Pajot President, Global Business Management, IMS Health

Gilles V.J. Pajot was appointed Executive Vice President and President, Global
Business Management of IMS Health in January 2006, having previously been
President, Europe, Middle East and Africa. He joined IMS in 1997 as Vice Chairman
and President of IMS, Europe. From 1995 to 1997, Mr. Pajot was Senior Vice
President of Pharmacia & Upjohn’s Europe, Middle East and Africa Region, and led
planning and analysis for the merger team that formed Pharmacia & Upjohn in 1995.
In more than 23 years at Pharmacia AB, he held positions of increasing responsibility,
which included running Pharmacia and Procordia subsidiaries in France 1979-1990,
and serving as CEO of global Pharmacia Biosystems AB 1990-1991. A French national,
he holds an MSc in biochemistry and chemistry (Rennes University) and a BSc
(Nantes University).

Dr. Anil Patel Action Research in Community Health & Development, India

Dr. Anil B. Patel founded Action Research in Community Health & Development
(ARCH) in 1978. ARCH is a not-for-profit, non-governmental organization, which for
25 years has run a community health project in Mangrol, Gujarat. This covers some
1,000 villages and is implemented by local Village Health Workers (VHWs), who are
trained and supervised by doctors. It has a high reputation for treatment of T.B., other
respiratory ailments, dysentery, malaria, leprosy and skin diseases. Dr. Patel obtained
a Diploma in Tropical Public Health from the London School of Hygienic and Tropical
Medicine in 1976 before completing an advanced course in Epidemiology and Medical
Statistics. He also worked for two years as a psychiatrist in Nottingham, UK.

Dr. Bernard Pécoul Executive Director, Drugs for Neglected Diseases initiative

Dr. Bernard Pécoul is Executive Director of the Drugs for Neglected Diseases initiative
(DNDi), a not-for-profit organization that seeks to develop and make available new
drugs for patients suffering from neglected diseases, such as sleeping sickness,
leishmaniasis and Chagas disease, that afflict the poor in developing countries. He
was previously Executive Director of Médecins Sans Frontières’ (MSF) Campaign for
Access to Essential Medicines from 1998 to 2003 and started with MSF in 1983 as
a volunteer physician in Honduras, Thailand and Malaysia, managing public health
projects for refugees. In 1988 he co-founded Epicentre, a epidemiological research
organization and was director of research and training until 1991. From 1991-1998,
he was Executive Director of MSF France, overseeing one hundred field projects in 40
countries. Dr. Pécoul has a medical degree from the University of Clermont-Ferrand,
France and an MPH from Tulane University, USA.

Ms. Joy Phumaphi Assistant Director-General, Family & Community Health, WHO

Ms. Joy Phumaphi has been the Assistant Director-General for Family and Community
Health and the Director-General’s Representative on Gender Equality at the World
Health Organization in Geneva, Switzerland, since 2003. Previously, she was Minister of
Health, Botswana, Vice Chair of the National AIDS Council and a Member of Parliament.
Joy Phumaphi is a distinguished African American Institute Fellow and a Commissioner
in the UN Secretary General’s Commission on HIV/AIDS and Governance in Africa. She
is a member of the Women’s Leadership Initiative for Microbicides and the Global HIV
Vaccine Enterprise Council. She has served on the UN Reference Group on Economics
(URGE) and on the UNDP Advisory Board for Africa.

Dr. Swati Piramal Director, Nicholas Piramal India, Ltd.

Dr. Swati A. Piramal is Director of Strategic Alliances & Communications at Nicholas
Piramal India Ltd., and is also responsible for R&D, new products and technologies,
knowledge management, and government policy. Under her leadership, Piramal has
made significant progress in discovery and patenting of NCEs, new drug delivery
systems, planning clinical trials, pathology and pharmacokinetics labs and technology
partnerships with leading global companies. She was a member of the WHO
Commission on Intellectual Property Rights, Innovation and Public Health and sits
on the Board of the Council of Scientific & Industrial Research (CSIR), New Delhi.
She chairs the National Committee on Biotechnology and is a Member of a Special
Committee to transform India into a knowledge power.

Dr. Jörg Reinhardt CEO, Novartis Vaccines & Diagnostics

Dr. Jörg Reinhardt is CEO of the new Novartis Vaccines & Diagnostics division, combining
Chiron Corporation’s vaccines and blood testing business. He was previously
Global Head of Development at Novartis’ Pharma division, overseeing the company’s
clinical, pharmaceutical, chemical and biotechnological product development, drug
safety assessment and regulatory affairs. Under his leadership, Novartis achieved an
outstanding record in development quality, speed and productivity, resulting in a full
product pipeline, widely recognized as one of the most successful in the industry.
Dr. Reinhardt chairs the Board of Directors of the Genomics Institute of the Novartis
Foundation in La Jolla, California. From 2001-04, he was a director of Morphosys AG,
a German company specialized in R&D of monoclonal antibodies.

Dr. Robert Ridley Director, Research and Training in Tropical Diseases

Dr. Robert Ridley is Director of the Special Program for Research and Training in
Tropical Diseases (TDR), co-sponsored by UNICEF, UNDP, the World Bank and the
WHO. He joined TDR in 1998, managing drug discovery research and helping set up
and run the Medicines for Malaria Venture (MMV), a public-private partnership to
discover and develop antimalarial drugs. His academic background covers organic
chemistry, biochemistry and molecular biology, with positions at the University of
Malawi (1980-83), McMaster University, Canada (1983-86) and Edinburgh University in
the U.K.(1986-92). In 1992, he moved to industry, working for F. Hoffmann-La-Roche
Ltd. in Basel (Switzerland), where he was a Vice Director in the Infectious Diseases
Drug Discovery department.

Ms. Anne-Laure Ropars Pharmaceutical R&D Policy Project

Ms. Anne-Laure Ropars trained and worked as a mechanical engineer, then took
a Masters degree in Political Economy and International Relations, before working
as a consultant specializing in European and developing country health systems
and policies. Her clients have included the EU-based pharmaceutical industry, the
Rockefeller and Bill and Melinda Gates Foundations, and government bodies (DFID,
USAID). Her projects span drug procurement in Sub-Saharan Africa, market-based
mechanisms to reduce essential drugs prices in Ghana, to drug reimbursement
policies in Europe. She joined the Pharmaceutical R&D Policy Project in 2004,
researching the pharmaceutical industry’s involvement in neglected diseases and
worked on developing incentive proposals. She now heads the London-based
research team under Dr. Mary Moran.

Prof. Hans Rosling International Health, Karolinska Institute, Sweden

Hans Rosling is Professor of International Health at Karolinska Institutet in Stockholm,
Sweden. His research has identified a new paralytic disease, konzo, that is induced by
malnutrition and dietary cyanide exposure. It occurs in poor rural populations in Africa.
He has also studied other links between poverty and health in Asia and Latin America.
He has been an adviser regarding vaccination and essential drugs in low-income
countries. He co-founded Médecins sans Frontiers in Sweden and is a member of the
International advisory group of the Swedish Academy of Science. He has pioneered
global health teaching in both under- and post-graduate training and co-founded
Gapminder (www.gapminder.org), a non-profit venture for development of software
that converts development statistics into moving, interactive and enjoyable graphics.
He won the 2006 Swedish award for science communication.

Prof. Manuel Ruiz De Chávez Executive President, FUNSALUD, Mexico

Prof. Manuel Ruiz De Chávez is Executive President of the Mexican Health Foundation
FUNSALUD. In the Mexican Ministry of Health, he was Director General of three
departments and also Undersecretary of Planning. His other government positions
include heading the Industrial Development National Laboratories, the Federal District
Health Services Institute and the medical services of the state oil company PEMEX.
He also worked for the Public Enterprise National Modernization Program and the
National Institutes of Health. He is Professor of Medicine at the National University of
Mexico, Director General of CIF BIOTEC (Medica Sur Foundation) and founded the
Mexican Foundation for the Innovation and Transfer of Technology of the Small and
Medium Enterprises. He has an MD from the National University of Mexico and an
MSc from the University of London.

Prof. Desmond Sheridan Academic Cardiology Unit, Imperial College, UK

Desmond John Sheridan has been Professor of Clinical Cardiology at the Imperial
College Faculty of Medicine, University of London and Head of Academic Cardiology
and Consultant Cardiologist at St.Mary’s Hospital since 1985. In 1978-1979, he was
awarded the British-American Fellowship from the Washington University, St. Louis.
He received his Ph.D. from the University of Newcastle upon Tyne in 1982. From 1981
to 1985, he served as Consultant Cardiologist at UCF, Cardiff. Prof. Sheridan worked
for the Medical Research Council on Physiology, Medicine and Infections from 1997 to
2001. In 2002, he started working for Pfizer, first as Cardiovascular Advisor and later
as a Consultant. Prof. Sheridan is a member of the European Society of Cardiology
and the British Cardiac Society.

Mr. Christopher Singer Executive Vice President and COO, PhRMA Prof. Koichi

Mr. Christopher A. Singer is Executive Vice President and COO of the Pharmaceutical
Research and Manufacturers of America (PhRMA), having previously worked for
GlaxoSmithKline for 13 years, rising to Vice President & Area Director for Latin
America and the Caribbean. Before that, he served as the Director of Government
Affairs for Pfizer. Earlier, he was a Professional Staff Member for the U.S. Congress
House Appropriations Committee and dealt with policy and budget oversight of the
National Institutes of Health and the Food and Drug Administration. He served as a
Health Policy Analyst for the Department of Health and Human Services and helped
develop policies on physicians’ and hospitals’ participation in the Federal Medicare
and Medicaid Programs. Mr. Singer entered government service through the
Presidential Management Program. He holds a Masters Degree in Public Health
Administration and a BSc in Economics.

Dr. Daniel Vasella President, IFPMA, Chairman & CEO, Novartis

Daniel Vasella, MD, was appointed Chairman of Novartis in April 1999, having served
as CEO and Head of the Group Executive Committee since the merger in 1996. His
Novartis career began at Sandoz Pharma in 1988, where he assumed the position of
CEO in 1994. Prior to joining Sandoz, Dr. Vasella held a number of medical positions
in Switzerland. Daniel Vasella is a member of the International Business Leaders
Advisory Council for the Mayor of Shanghai and of the International Board of Governors
of the Peres Center for Peace. In 2002, Dr. Vasella was awarded an honorary doctorate
by the Faculty of Medicine of the University of Basel.

Mr. Michael Waldholz Managing Editor, Bloomberg

Mr. Michael Waldholz joined Bloomberg News in June, 2005 as Senior Editor and was
named a Managing Editor in December, 2005, overseeing Bloomberg’s health and
science staff of 36 reporters and editors in bureaus in the U.S., Europe and Asia. For
25 years, until April 2005, Mr. Waldholz served as Chief Medical and Science Reporter
and News Editor at the Wall Street Journal, covering the drug and biotech industries,
as well as personal and public health issues. He led a team of reporters that won the
1996 Pulitzer Prize for national reporting on breakthrough AIDS medicines. He is the
author of “Curing Cancer”, published in 1997, and co-author of “Genome”, published
in 1990.

Dr. Michel Zaffran Deputy Executive Secretary, GAVI Alliance

Michel Zaffran has been Deputy Executive Secretary of the GAVI Alliance, heading the
Technical and Policy team, since February 2006. An engineer, he then studied Tropical
Epidemiology at the Department of Tropical Hygiene and Public Health, Heidelberg
University. He worked for the French Government and NGO the Groupe de Recherches
et d’Echanges Technologiques before joining the WHO in 1988. He became Program
Manager in the Vaccines & Biologicals Department in 1999 and helped conceive the
Global Alliance for Vaccines & Immunization (now GAVI Alliance). In 2003, he became
Coordinator of the Access to Technologies team in the Immunization, Vaccines &
Biologicals Department, leading WHO efforts in vaccine quality, management,
supply and immunization financing, and also represented WHO on the GAVI
Financing Task Force.

Mr. Thomas Zeller Deputy Director, Thematic & Technical Resources Department, Swiss Agency for Development & Cooperation

Thomas Zeller is Deputy Director of the Thematic and Technical Resources Department
of the Swiss Agency for Development and Cooperation (SDC). He qualified as an
agricultural engineer at the Swiss Federal Institute of Technology in Zürich. He has
20 years of field experience in rural and agricultural development in Africa and Latin
America, and more than 10 years experience at the HQ of SDC in development policymaking
in agriculture, water and social development, including health and education.
During his career, he has also worked for the German Agency for Development and
Cooperation (GTZ). His vision and strengths are integrated approaches, including
multi-stakeholder, public-private partnerships.

Dr. Howard Zucker Assistant Director-General, Health Technology & Pharmaceuticals, WHO

Dr. Howard A. Zucker is Director-General of Health Technology and Pharmaceuticals
at the World Health Organization. He was a White House Fellow and Deputy Assistant
Secretary of Health at the U.S. Department of Health and Human Services. Dr. Zucker
received his M.D. from George Washington University School of Medicine. His
specializations include paediatrics, anaesthesiology, paediatric critical care medicine,
paediatric anaesthesiology and paediatric cardiology. He was an Assistant Professor
at Yale University School of Medicine, an Associate Professor at Columbia University
College of Physicians and Surgeons, Adjunct Associate Professor at Cornell University
Medical School and on the faculty at the National Institutes of Health. He has J.D.
from Fordham University School of Law and a Masters from Columbia Law School.
Dr. Zucker is a member of the Council on Foreign Relations.


Supporting documents